14,571 Shares in Viking Therapeutics, Inc. (NASDAQ:VKTX) Acquired by NEOS Investment Management LLC

NEOS Investment Management LLC acquired a new stake in Viking Therapeutics, Inc. (NASDAQ:VKTXFree Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 14,571 shares of the biotechnology company’s stock, valued at approximately $271,000.

Several other large investors have also recently added to or reduced their stakes in the company. Campbell & CO Investment Adviser LLC acquired a new position in shares of Viking Therapeutics in the fourth quarter valued at about $545,000. Eagle Asset Management Inc. bought a new position in shares of Viking Therapeutics during the fourth quarter worth approximately $4,872,000. Dorsey & Whitney Trust CO LLC acquired a new stake in shares of Viking Therapeutics in the fourth quarter valued at approximately $341,000. Steward Partners Investment Advisory LLC boosted its stake in shares of Viking Therapeutics by 121.4% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 38,746 shares of the biotechnology company’s stock valued at $721,000 after buying an additional 21,246 shares during the period. Finally, Nemes Rush Group LLC acquired a new stake in Viking Therapeutics during the fourth quarter worth approximately $93,000. Institutional investors own 76.03% of the company’s stock.

Insider Buying and Selling at Viking Therapeutics

In other news, COO Marianna Mancini sold 281,425 shares of the business’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $78.66, for a total transaction of $22,136,890.50. Following the sale, the chief operating officer now directly owns 348,508 shares in the company, valued at $27,413,639.28. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, CFO Greg Zante sold 66,756 shares of the firm’s stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $74.69, for a total transaction of $4,986,005.64. Following the completion of the transaction, the chief financial officer now directly owns 174,854 shares of the company’s stock, valued at approximately $13,059,845.26. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Marianna Mancini sold 281,425 shares of the company’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $78.66, for a total value of $22,136,890.50. Following the completion of the sale, the chief operating officer now owns 348,508 shares in the company, valued at approximately $27,413,639.28. The disclosure for this sale can be found here. Corporate insiders own 4.70% of the company’s stock.

Viking Therapeutics Price Performance

Shares of NASDAQ:VKTX opened at $55.01 on Friday. Viking Therapeutics, Inc. has a one year low of $8.28 and a one year high of $99.41. The firm has a 50 day simple moving average of $70.46 and a 200 day simple moving average of $46.98.

Viking Therapeutics (NASDAQ:VKTXGet Free Report) last announced its quarterly earnings results on Wednesday, April 24th. The biotechnology company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.01. During the same period in the prior year, the firm earned ($0.25) earnings per share. Sell-side analysts forecast that Viking Therapeutics, Inc. will post -1.08 EPS for the current fiscal year.

Wall Street Analyst Weigh In

VKTX has been the subject of a number of recent analyst reports. StockNews.com upgraded Viking Therapeutics to a “sell” rating in a research report on Friday, May 31st. HC Wainwright reaffirmed a “buy” rating and set a $90.00 price objective on shares of Viking Therapeutics in a research report on Tuesday. BTIG Research raised their target price on shares of Viking Therapeutics from $100.00 to $125.00 and gave the company a “buy” rating in a report on Tuesday, March 26th. Jefferies Financial Group began coverage on shares of Viking Therapeutics in a report on Thursday, March 7th. They set a “buy” rating and a $110.00 price target for the company. Finally, Maxim Group reissued a “buy” rating and issued a $120.00 price objective on shares of Viking Therapeutics in a research note on Tuesday. One analyst has rated the stock with a sell rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Viking Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $112.38.

Check Out Our Latest Report on Viking Therapeutics

Viking Therapeutics Company Profile

(Free Report)

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.

Read More

Want to see what other hedge funds are holding VKTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Viking Therapeutics, Inc. (NASDAQ:VKTXFree Report).

Institutional Ownership by Quarter for Viking Therapeutics (NASDAQ:VKTX)

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.